Clik here to view.
Leerink Swann starts Achillion at outperform
Leerink Swann has initiated coverage of Achillion Pharmaceuticals (NASDAQ:ACHN) with an “outperform” rating and 12-month valuation of $10 a share. The stock closed at $5.81 on Monday. Analyst Howard...
View ArticleClik here to view.
Leerink Swann starts Verastem at outperform
Leerink Swann has initiated coverage of Verastem (NASDAQ:VSTM) with an “outperform” rating and 12-month valuation of $15. The closed at $11.10 on Tuesday. “Built on discoveries and technologies...
View ArticleClik here to view.
Leerink Swann starts OvaScience at outperform
Leerink Swann has initiated coverage of OvaScience (OTCBB:OVSC) with an “outperform” rating and $11 valuation. The stock was listed Friday and is expected to begin trading today. “In an area that has...
View ArticleClik here to view.
OncoGenex’s OGX-427 drug gaining investor attention
Even though OncoGenex Pharmaceuticals (NASDAQ:OGXI) and its pivotal programs with lead oncology candidate, custirsen, are being closely followed, investors are beginning to notice the company’s second...
View ArticleClik here to view.
Leerink starts Ambit Bioscience at outperform
Leerink Swann has initiated coverage of Ambit Bioscience (NASDAQ:AMBI) with an “outperform” rating and $14 valuation, saying it sees Ambit’s quizartinib as the best-in-class FLT3 inhibitor, which...
View ArticleClik here to view.
Leerink starts OncoMed at outperform
Leerink Swann has initiated coverage of OncoMed Pharmaceuticals (NASDAQ:OMED) with an “outperform” rating and price target of $27. The stock closed at $19.84 on Friday. “OncoMed is the longest-standing...
View ArticleClik here to view.
Leerink starts Immune Design at outperform
Leerink Partners has launched coverage of Immune Design (NASDAQ:IMDZ) with an “outperform” rating and 12-month price target of $25. The stock was quoted at $12.15 near the mid-session on Monday. The...
View Article
